I think I can get two, maybe three, papers out of this:
- Estimate the joint probability of success and Plan Normalized duration.
- Estimate a model similar to EK's model of market vs scientific failure.
- Estimate a model similar to EK's model of market vs scientific failure, incorporating the previous point.
- Develop a structural model that includes a policy parameter relevant to a policy the CBO cares about (Not a high priority yet).
## Questions:
@ -11,6 +11,18 @@ I think I can get two, maybe three, papers out of this:
- What is the effect of `policy` on phase completion and phase transition?
- What is the impact of surragate endpoints on phase transition completion? on phase transition?
## Value Proposition:
Attempt to build a "cannonical" probabalistic model of the clinical trials process, which will allow for a simple way to test hypotheses regarding the impact of policies and practices on drug development.
### Desired Attributes
- straightforward to re-estimate model and add extensions.
- [Data Processing](https://gitea.kgjk.icu/Research/ClinicalTrialsDataProcessing) is separate and mostly automated.
- An input data standard exists.
- Inference method is well supported.
- Documentation of code exists, and is useful.
# Models
The general benefit I can provide is to:
@ -51,10 +63,12 @@ The probabalistic model could then be used to answer various questions, includin
It would also be straightforward to develop simulations from this approach, as the probabilities are right there.
# Estimation Strategy
Probably use a non-parametric bayesian approach to estimating the probability densities.
[[AbrantesMetz-Adams-and-Metz]] use a mixed state proportional hazards model.
Probably use a non-parametric (np-bayesian?) approach to estimating the probability densities.
## Phase Completion Probabilities:
[[AbrantesMetz-Adams-and-Metz]] use a mixed state proportional hazards model.
The goal is to estimate
@ -70,6 +84,8 @@ I may also include the combined phases
I think there might be a way of condensing these using "phase endpoints" as a marker, and not the phase type itself.